Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulation

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Jin, Jun O ^a   Zhang, Wei ^a   Wong, Ka Wing ^a   Kwak, Minseok ^b   Van Driel, Ian R ^c   Yu, Qing ^d  

^a FUDAN UNIVERSITY   (China)

^b Pukyong National University   (South Korea)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FORSYTH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; CD1C ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FOXP3; 3-(6-ISOBUTYL-9-METHOXY-1,4-DIOXO-1,2,3,4,6,7,12,12A-OCTAHYDROPYRAZINO(1',2'-1,6)PYRIDO(3,4-B)INDOL-3-YL)PROPIONIC ACID TERT-BUTYL ESTER; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ADENOSINE; TUMOR PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; MYELOID DENDRITIC CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CYTOLOGY; DEFICIENCY; DENDRITIC CELL; DRUG EFFECTS; GENE SILENCING; GENETICS; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION;

ADENOSINE; ATP-BINDING CASSETTE TRANSPORTERS; DENDRITIC CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MYELOID CELLS; NEOPLASM PROTEINS; PHOSPHORYLATION; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84905859970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104753     Document Type: Article

References (45)

1. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer 2: 48-58. (Pubitemid 37328807)
2. Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nature reviews Cancer 10: 147-156.
3. Ma MT, He M, Wang Y, Jiao XY, Zhao L, et al. (2013) MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer letters 339: 107-115.
4. Lobo NA, Shimono Y, Qian D, Clarke MF (2007) The biology of cancer stem cells. Annual review of cell and developmental biology 23: 675-699.
5. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nature reviews Drug discovery 5: 219-234. (Pubitemid 43336035)
6. Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, et al. (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116: 4077-4085.
7. Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Current molecular pharmacology 1: 93-105.
8. Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, et al. (2007) Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25: 411-417.
9. Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, et al. (2007) A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 3276-3285.
10. Palucka K, Banchereau J (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39: 38-48.
11. Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nature reviews Immunology 7: 19-30. (Pubitemid 46020824)
12. Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annual review of immunology 21: 685-711. (Pubitemid 37174545)
13. Torres-Aguilar H, Blank M, Jara LJ, Shoenfeld Y (2010) Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmunity reviews 10: 8-17.
14. Lutz MB, Schuler G (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends in immunology 23: 445-449. (Pubitemid 35015188)
15. Lutz MB (2012) Therapeutic potential of semi-mature dendritic cells for tolerance induction. Frontiers in immunology 3: 123.
16. Maldonado RA, von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Advances in immunology 108: 111-165.
17. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, et al. (1999) Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer research 59: 455-461. (Pubitemid 29048883)
18. van de Ven R, Lindenberg JJ, Reurs AW, Scheper RJ, Scheffer GL, et al. (2012) Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP). Immunology and cell biology 90: 206-215.
19. van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, et al. (2006) Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. Journal of immunology 176: 5191-5198.
20. Schroeijers AB, Reurs AW, Scheffer GL, Stam AG, de Jong MC, et al. (2002) Up-regulation of drug resistance-related vaults during dendritic cell development. Journal of immunology 168: 1572-1578. (Pubitemid 34135751)
21. Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, et al. (2006) Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. The Journal of biological chemistry 281: 23812-23823. (Pubitemid 44274157)
22. Lozza L, Farinacci M, Fae K, Bechtle M, Staber M, et al. (2013) Crosstalk between human DC subsets promotes antibacterial activity and CD8 T-cell stimulation in response to bacille Calmette-Guerin. European journal of immunology.
23. Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, et al. (2011) Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. The Journal of experimental medicine 208: 235-249.
24. Boks MA, Kager-Groenland JR, Haasjes MS, Zwaginga JJ, van Ham SM, et al. (2012) IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction - a comparative study of human clinical-applicable DC. Clinical immunology 142: 332-342.
25. Rutella S, Danese S, Leone G (2006) Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440. (Pubitemid 44316106)
26. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. Journal of immunology 166: 3837-3845. (Pubitemid 32224909)
27. Grohmann U, Belladonna ML, Bianchi R, Orabona C, Ayroldi E, et al. (1998) IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 9: 315-323. (Pubitemid 28462752)
28. Laupeze B, Amiot L, Bertho N, Grosset JM, Lehne G, et al. (2001) Differential expression of the efflux pumps P-glycoprotein and multidrug resistance-associated protein in human monocyte-derived dendritic cells. Human immunology 62: 1073-1080. (Pubitemid 32971384)
29. Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, et al. (1998) A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proceedings of the National Academy of Sciences of the United States of America 95: 6924-6929. (Pubitemid 28278083)
30. van de Ven R, Scheffer GL, Reurs AW, Lindenberg JJ, Oerlemans R, et al. (2008) A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood 112: 2353-2359.
31. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, et al. (2000) The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103: 757-768.
32. van de Ven R, Scheffer GL, Scheper RJ, de Gruijl TD (2009) The ABC of dendritic cell development and function. Trends in immunology 30: 421-429.
33. Chen W, Hara K, Tian Q, Zhao K, Yoshitomi T (2007) Existence of small slow-cycling Langerhans cells in the limbal basal epithelium that express ABCG2. Experimental eye research 84: 626-634. (Pubitemid 46400630)
34. Castiello L, Sabatino M, Jin P, Clayberger C, Marincola FM, et al. (2011) Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer immunology, immunotherapy: CII 60: 457-466.
35. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485. (Pubitemid 37487170)
36. Bates S, Kang M, Meadows B, Bakke S, Choyke P, et al. (2001) A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 92: 1577-1590. (Pubitemid 32947844)
37. Kusmartsev S, Gabrilovich DI (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer metastasis reviews 25: 323-331. (Pubitemid 44922353)
38. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, et al. (2007) Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer immunology, immunotherapy: CII 56: 48-59. (Pubitemid 44812446)
39. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108: 804-811. (Pubitemid 44154611)
40. Wang HY, Wang RF (2007) Regulatory T cells and cancer. Current opinion in immunology 19: 217-223. (Pubitemid 46356965)
41. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer cell 15: 195-206.
42. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P (1998) Dendritic cell survival and maturation are regulated by different signaling pathways. The Journal of experimental medicine 188: 2175-2180. (Pubitemid 28562533)
43. Qian C, Jiang X, An H, Yu Y, Guo Z, et al. (2006) TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood 108: 2307-2315. (Pubitemid 44497514)
44. Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, et al. (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. The Cochrane database of systematic reviews 1: CD004386.
45. van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, et al. (2012) Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. The Cochrane database of systematic reviews 9: CD006247.